Danaher's Beckman Coulter Unit to Ship New SARS-CoV-2 Antibody Test
August 24 2020 - 9:17AM
Dow Jones News
By Keith Collins
Danaher Corp.'s Beckman Coulter division Monday said it would
begin shipping its Access SARS-CoV-2 Immunoglobulin M antibody test
to U.S. diagnostics labs.
The new test demonstrated 99.9% specificity against 1,400
negative samples and 98.3% sensitivity at 15 to 30 days after the
onset of symptoms, Beckman Coulter said.
The company said its test targets antibodies that recognize the
receptor binding domain of the spike protein that SARS-CoV-2 uses
to bind to a human cell receptor. This is significant as antibodies
that target the RBD have the potential to be neutralizing and thus
prevent future infection by blocking the virus from entering the
cell, the company said.
The test provides information about an individual's immune
status with a positive predictive value of 95.5% even when disease
incidence in a population is as low as 3%, said Julie Sawyer
Montgomery, the president of Beckman Coulter.
The Brea, Calif., company also said it is awaiting U.S. Food and
Drug Administration emergency-use authorization for its
interleukin-6 test, which could provide valuable information in
clinical decision-making for Covid-19 patients.
Write to Keith Collins at keith.collins@dowjones.com
(END) Dow Jones Newswires
August 24, 2020 09:02 ET (13:02 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Danaher (NYSE:DHR)
Historical Stock Chart
From Aug 2024 to Sep 2024
Danaher (NYSE:DHR)
Historical Stock Chart
From Sep 2023 to Sep 2024